IP Library Granted Patent US 7,612,188
Granted Patent B2
US 7,612,188 · App. 11/555,769 · Granted Nov 3, 2009

Modified vitamin K. dependent polypeptides

Assignee: Regents of the University of Minnesota
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,612,188
App. No.
11/555,769
Granted
Nov 3, 2009
Kind
B2
Abstract

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Claims (7)

1. An isolated nucleic acid comprising a nucleic acid sequence encoding a vitamin K-dependent polypeptide that increases clot formation comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, wherein said modified GLA domain comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 4 with two to five amino acid substitutions, which include a glutamine residue substituted at amino acid position 10 and an amino acid substitution at one or more amino acid positions selected from positions 28, 32, 33, 34.

2. A vector comprising the nucleic acid of claim 1 .

3. A host cell comprising the vector of claim 2 .

4. An isolated nucleic acid comprising a nucleic acid sequence encoding a mutant Factor VII or VIIa polypeptide that increases clot formation, wherein said polypeptide comprises a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native Factor VII or Factor VIIa polypeptide, said modified GLA domain comprising two to five amino acid substitutions, which include a glutamine residue substituted at amino acid position 10 and an amino acid substitution at one or more amino acid positions selected from positions 28, 32, 33, and 34 of SEQ ID NO:3 or SEQ ID NO:4.

5. A vector comprising a nucleic acid of claim 4 .

6. A host cell comprising the vector of claim 5 .

7. A method for producing a vitamin K-dependent polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native vitamin K-dependent polypeptide, wherein said modified GLA domain comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 4 with two to five amino acid substitutions, which include a glutamine residue substituted at amino acid position 10 and an amino acid substitution at one or more amino acid positions selected from positions 28, 32, 33, and 34 of SEQ ID NO: 3 or SEQ ID NO: 4, the method comprising (a) culturing a host cell of claim 3 under conditions which permit expression of the polypeptide, and (b) recovering the polypeptide.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 12, 2015
From: UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035650/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2009
From: NELSESTUEN, GARY L.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 022759/0955 →
Continuity (5)
Continuation 1029833000 · Nov 18, 2002
Continuation In Part 0949759100 · Feb 3, 2000
Continuation In Part 0930223900 · Apr 29, 1999
Continuation In Part 0895563600 · Oct 23, 1997
Related Publication 20070161561A1 · Jul 12, 2007